Developer docs
API playgroundTry for free, no card

Search company profiles

B-Secur

Full company profile

uuid0000tnq

Namestring
B-Secur
Legal namestring
B-Secur Limited
Websiteurl
b-secur.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

B-Secur Limited is a Belfast, Northern Ireland-based medical technology company that develops FDA 510(k)-cleared ECG and bioimpedance signal-processing software for integration into third-party devices. The company's core product, the HeartKey algorithm suite, processes cardiac signals captured from either dry or wet electrodes and supports spot-check or continuous monitoring, deployable on-device or in the cloud, with a 2024 FDA-cleared HeartKey Rhythm addition for proactive cardiac care. Underlying capabilities include proprietary ECG signal denoising, dry-electrode signal conditioning, signal quality assessment, and bioimpedance analysis, backed by a clinical validation corpus of more than 2 million hours of data and over 7 billion heartbeats analyzed, and supported by an internal preclinical testing facility called ABEL (Advanced Biosensing Engineering Lab).

The company operates a B2B technology-licensing and SaaS model. Revenue is generated through licensing HeartKey algorithms to consumer wearable manufacturers (smartwatches, rings, patches, clothing-integrated devices), medical device OEMs (ambulatory monitors, Holter devices, patches), and hospital systems for remote patient monitoring, supplemented by cloud-based SaaS deployments, professional services covering regulatory and clinical strategy, and ECG hardware design support. Distribution is direct enterprise sales with technical conversations between engineers as the entry point, complemented by a semiconductor partner ecosystem (STMicroelectronics, Texas Instruments, NXP, Analog Devices) that positions HeartKey within OEM reference designs.

B-Secur is venture-backed, having raised approximately $27.4 million across multiple rounds between 2015 and 2023 from investors including Kernel Capital, Accelerated Digital Ventures (ADV), Wharton Asset Management, First Capital Ventures, Co-FundNI, and the British Business Bank's Future Fund. The company employs roughly 100 people across offices in the United Kingdom, Ireland, and the United States, with a Country Manager presence in India, and holds ISO 13485:2016 certification (TÜV SÜD) in addition to its FDA clearances. Named commercial partners and customers include WHOOP, Biotricity, Sensr, Orlando Health, FIRMINIQ, SweatWorks, and Galen Data.

Short descriptiontext

B-Secur is a Belfast-based medical technology company that licenses FDA-cleared HeartKey ECG and bioimpedance algorithms and SaaS to consumer wearable, medical device, and hospital system customers for medical-grade cardiac monitoring integration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ECG algorithm licensing, biosensing technology, cardiac monitoring software, medical device integration, wearable health technology
Industry3 codes
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Monitoring Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Licenses FDA-cleared ECG algorithms and biosensing technology to device manufacturers for integration into consumer wearables, medical devices, and other products.

b-secur.com
2Software-as-a-Service (SaaS)
TypeSubscription Recurring
Description

Cloud-based ECG analysis solutions deployed as SaaS for customers requiring cloud processing rather than on-device deployment.

b-secur.com
3Professional Services
TypeProfessional Services
Description

Regulatory strategy, preclinical testing support, and Quality Management Systems guidance for device manufacturers navigating FDA and regulatory submission processes.

b-secur.com
4Hardware Partnership Services
TypeProfessional Services
Description

Electrode design, materials selection, ECG electronic schematic, PCB design, mechanical design, and test strategy services for hardware partners.

b-secur.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1HeartKey
Description

FDA-cleared ECG algorithm suite for dry or wet electrodes, spot-check or continuous monitoring, and on-device or cloud deployment.

b-secur.com
Core offering1 text field

B-Secur develops and licenses the FDA 510(k)-cleared HeartKey algorithm suite for ECG and bioimpedance signal processing, targeting device manufacturers across consumer wearables, medical devices, and hospital systems. The company also provides supporting services including dry electrode hardware design, preclinical validation through ABEL (Advanced Biosensing Engineering Lab), and regulatory strategy support for FDA and quality management system submissions. Deployment options include on-device or cloud-based processing for both dry and wet electrode configurations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98.3% sensitivity and 100% specificity for AF detection from 30-second wrist ECGs
+3 more records
Product overview1 text field

B-Secur is a B2B medical software (SaaS) company offering end-to-end ECG and bioimpedance solutions for biosensing in consumer wearables, medical devices, and clinical applications. The core product is HeartKey®, an FDA 510(k)-cleared algorithm suite providing cardiac rhythm analysis, augmented by hardware design services, preclinical validation through ABEL (Advanced Biosensing Engineering Lab), and regulatory strategy support. The company positions itself as a partner for device manufacturers, offering plug-in solutions at any stage from signal capture to validated algorithms, deployable on-device or cloud-based.

Product and service6 records
1HeartKey
CategoryCore ECG Algorithm Platform
Description

FDA 510(k)-cleared algorithm suite for ECG analysis supporting dry or wet electrodes, spot-check or continuous monitoring, and on-device or cloud deployment for cardiac rhythm detection; licensed to device manufacturers for integration into their products.

2HeartKey Rhythm
CategoryCardiac Rhythm Analysis Sub-product
Description

FDA-cleared cardiac rhythm monitoring solution providing proactive and efficient cardiac care with enhanced rhythm analysis capabilities for device manufacturers.

3HeartKey 2.0
CategoryECG Algorithm Suite
Description

Next-generation EKG algorithm suite providing breakthrough medical accuracy through enhanced signal clarity and noise reduction, with FDA-cleared health data and actionable wellness insights.

4ABEL (Advanced Biosensing Engineering Lab)
CategoryPreclinical Validation Service
Description

Pressure-testing service for the sensing stack providing bench testing and preclinical validation to uncover ECG program limitations with evidence-based guidance for device manufacturers.

5ECG Hardware Design Services
CategoryHardware Design Service
Description

Hardware expertise partnership covering electrode design, materials selection, ECG electronic schematic, PCB design, mechanical design, and test strategy for ECG and bioimpedance signal capture.

6Regulatory & Clinical Strategy Services
CategoryRegulatory Consulting Service
Description

Preclinical study design, Quality Management Systems, and 510(k) strategy support services to help device manufacturers turn prototypes into market-ready medical products.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Orlando Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Clinical wearable pilot program partnership with Orlando Health through its Orlando Health Ventures arm. B-Secur contributes ECG software technology to WHOOP wristbands used for monitoring COPD patients post-discharge at Orlando Health South Lake Hospital, aiming to improve patient care and reduce readmissions.

b-secur.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-05
Description

Integration of B-Secur's FDA-cleared ECG software technology into WHOOP wristbands as part of the Orlando Health clinical pilot program. WHOOP devices measure up to 50 metrics including clinical-grade ECGs.

3Sensr
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-05
Description

Partner in the Orlando Health clinical wearable pilot program, providing monitoring infrastructure and data management capabilities.

b-secur.com
4FIRMINIQ
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

Strategic partnership to transform cardiovascular health management through combined expertise in cardiac monitoring solutions.

b-secur.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

B-Secur

Cardiac Monitoring Softwareb-secur.com

B-Secur is a Belfast-based medical technology company that licenses FDA-cleared HeartKey ECG and bioimpedance algorithms and SaaS to consumer wearable, medical device, and hospital system customers for medical-grade cardiac monitoring integration.

What B-Secur does

B-Secur Limited is a Belfast, Northern Ireland-based medical technology company that develops FDA 510(k)-cleared ECG and bioimpedance signal-processing software for integration into third-party devices. The company's core product, the HeartKey algorithm suite, processes cardiac signals captured from either dry or wet electrodes and supports spot-check or continuous monitoring, deployable on-device or in the cloud, with a 2024 FDA-cleared HeartKey Rhythm addition for proactive cardiac care. Underlying capabilities include proprietary ECG signal denoising, dry-electrode signal conditioning, signal quality assessment, and bioimpedance analysis, backed by a clinical validation corpus of more than 2 million hours of data and over 7 billion heartbeats analyzed, and supported by an internal preclinical testing facility called ABEL (Advanced Biosensing Engineering Lab).

The company operates a B2B technology-licensing and SaaS model. Revenue is generated through licensing HeartKey algorithms to consumer wearable manufacturers (smartwatches, rings, patches, clothing-integrated devices), medical device OEMs (ambulatory monitors, Holter devices, patches), and hospital systems for remote patient monitoring, supplemented by cloud-based SaaS deployments, professional services covering regulatory and clinical strategy, and ECG hardware design support. Distribution is direct enterprise sales with technical conversations between engineers as the entry point, complemented by a semiconductor partner ecosystem (STMicroelectronics, Texas Instruments, NXP, Analog Devices) that positions HeartKey within OEM reference designs.

B-Secur is venture-backed, having raised approximately $27.4 million across multiple rounds between 2015 and 2023 from investors including Kernel Capital, Accelerated Digital Ventures (ADV), Wharton Asset Management, First Capital Ventures, Co-FundNI, and the British Business Bank's Future Fund. The company employs roughly 100 people across offices in the United Kingdom, Ireland, and the United States, with a Country Manager presence in India, and holds ISO 13485:2016 certification (TÜV SÜD) in addition to its FDA clearances. Named commercial partners and customers include WHOOP, Biotricity, Sensr, Orlando Health, FIRMINIQ, SweatWorks, and Galen Data.

B-Secur firmographics

Firmographics
Name
B-Secur
Legal name
B-Secur Limited
Website
https://b-secur.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
B-Secur is a Belfast-based medical technology company that licenses FDA-cleared HeartKey ECG and bioimpedance algorithms and SaaS to consumer wearable, medical device, and hospital system customers for medical-grade cardiac monitoring integration.
Ownership category
akta.pro rank

B-Secur industry classification

Industry
Product category
Cardiac Monitoring Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • ECG algorithm licensing
  • Biosensing technology
  • Cardiac monitoring software
  • Medical device integration
  • Wearable health technology

Where B-Secur is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

B-Secur business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Technology Licensing: Licenses FDA-cleared ECG algorithms and biosensing technology to device manufacturers for integration into consumer wearables, medical devices, and other products.
  2. Software-as-a-Service (SaaS): Cloud-based ECG analysis solutions deployed as SaaS for customers requiring cloud processing rather than on-device deployment.
  3. Professional Services: Regulatory strategy, preclinical testing support, and Quality Management Systems guidance for device manufacturers navigating FDA and regulatory submission processes.
  4. Hardware Partnership Services: Electrode design, materials selection, ECG electronic schematic, PCB design, mechanical design, and test strategy services for hardware partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

B-Secur product offering

Product offering

Core offering

B-Secur develops and licenses the FDA 510(k)-cleared HeartKey algorithm suite for ECG and bioimpedance signal processing, targeting device manufacturers across consumer wearables, medical devices, and hospital systems. The company also provides supporting services including dry electrode hardware design, preclinical validation through ABEL (Advanced Biosensing Engineering Lab), and regulatory strategy support for FDA and quality management system submissions. Deployment options include on-device or cloud-based processing for both dry and wet electrode configurations.

Product overview

B-Secur is a B2B medical software (SaaS) company offering end-to-end ECG and bioimpedance solutions for biosensing in consumer wearables, medical devices, and clinical applications. The core product is HeartKey®, an FDA 510(k)-cleared algorithm suite providing cardiac rhythm analysis, augmented by hardware design services, preclinical validation through ABEL (Advanced Biosensing Engineering Lab), and regulatory strategy support. The company positions itself as a partner for device manufacturers, offering plug-in solutions at any stage from signal capture to validated algorithms, deployable on-device or cloud-based.

Differentiator

Problem solved

Functional benefit

Brands

  • HeartKey: FDA-cleared ECG algorithm suite for dry or wet electrodes, spot-check or continuous monitoring, and on-device or cloud deployment.

Products and services

  • HeartKey FDA 510(k)-cleared algorithm suite for ECG analysis supporting dry or wet electrodes, spot-check or continuous monitoring, and on-device or cloud deployment for cardiac rhythm detection; licensed to device manufacturers for integration into their products.
  • HeartKey Rhythm FDA-cleared cardiac rhythm monitoring solution providing proactive and efficient cardiac care with enhanced rhythm analysis capabilities for device manufacturers.
  • HeartKey 2.0 Next-generation EKG algorithm suite providing breakthrough medical accuracy through enhanced signal clarity and noise reduction, with FDA-cleared health data and actionable wellness insights.
  • ABEL (Advanced Biosensing Engineering Lab) Pressure-testing service for the sensing stack providing bench testing and preclinical validation to uncover ECG program limitations with evidence-based guidance for device manufacturers.
  • ECG Hardware Design Services Hardware expertise partnership covering electrode design, materials selection, ECG electronic schematic, PCB design, mechanical design, and test strategy for ECG and bioimpedance signal capture.
  • Regulatory & Clinical Strategy Services Preclinical study design, Quality Management Systems, and 510(k) strategy support services to help device manufacturers turn prototypes into market-ready medical products.

Quantifiable outcome

  • 98.3% sensitivity and 100% specificity for AF detection from 30-second wrist ECGs
  • +3 more outcomes

Companies that use B-Secur

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

B-Secur technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

B-Secur partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Orlando HealthcoreStrategic or Co-development Partner · 5 November 2025Clinical wearable pilot program partnership with Orlando Health through its Orlando Health Ventures arm. B-Secur contributes ECG software technology to WHOOP wristbands used for monitoring COPD patients post-discharge at Orlando Health South Lake Hospital, aiming to improve patient care and reduce readmissions.
  • WHOOPcoreTechnology or Integration · 5 November 2025Integration of B-Secur's FDA-cleared ECG software technology into WHOOP wristbands as part of the Orlando Health clinical pilot program. WHOOP devices measure up to 50 metrics including clinical-grade ECGs.
  • SensrcoreTechnology or Integration · 5 November 2025Partner in the Orlando Health clinical wearable pilot program, providing monitoring infrastructure and data management capabilities.
  • FIRMINIQminorStrategic or Co-development Partner · 21 August 2024Strategic partnership to transform cardiovascular health management through combined expertise in cardiac monitoring solutions.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

B-Secur competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

B-Secur social profiles

Digital presence

B-Secur compliance and trust

Trust signal

Compliance2 records

B-Secur financial estimates

Financial estimate

Revenue estimate

Valuation estimate

B-Secur leadership team

Management profile

Number of profiles

Profiles15 records

B-Secur funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

B-Secur M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B-Secur

What does B-Secur do?

B-Secur develops and licenses the FDA 510(k)-cleared HeartKey algorithm suite for ECG and bioimpedance signal processing, targeting device manufacturers across consumer wearables, medical devices, and hospital systems. The company also provides supporting services including dry electrode hardware design, preclinical validation through ABEL (Advanced Biosensing Engineering Lab), and regulatory strategy support for FDA and quality management system submissions. Deployment options include on-device or cloud-based processing for both dry and wet electrode configurations.

Is B-Secur a public or private company?

B-Secur is a private company. It is classified as venture growth investor backed and is currently operating.

When was B-Secur founded?

B-Secur was founded in 2016. It employs 11 to 50 people.

Where is B-Secur based?

B-Secur is headquartered in Belfast, United Kingdom, in the Europe region.

How does B-Secur make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are software-as-a-Service (SaaS), professional Services and hardware Partnership Services.

Does B-Secur have an API?

No public API is recorded for B-Secur.

What industry is B-Secur in?

B-Secur's product category is Cardiac Monitoring Software. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of CRACAQAC, ECG/EKG & Heart Rhythm Monitors (Consumer). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogBeacon Hospital Research Institute and B-Secur Launch Pilot to Bring ECG Data from Consumer Wearables Directly into Clinical CareBeacon Hospital Research Institute and B-Secur launched a pilot to bring ECG data from consumer wearables into clinical workflow. The pilot evaluates B-Secur's device-agnostic HeartKey technology, with results expected within six months. It aims to bridge the gap between patient-generated wearable data and clinician access.FinancialContent Business PageBeacon Hospital Research Institute and B-Secur Launch Pilot to Bring ECG Data from Consumer Wearables Directly into Clinical CareBeacon Hospital Research Institute and B-Secur launched a pilot to bring ECG data from consumer wearables into clinical workflow. The pilot evaluates B-Secur's device-agnostic HeartKey technology, with results expected within six months. It aims to bridge the gap between wearable-generated data and clinician needs.FinancialContent Business PageB-Secur Launches ECG Test System to Address Wearable Industry's Signal Quality Testing GapB-Secur launched its ECG Test System (ETS) to provide wearable device manufacturers with an objective, standardized measure of ECG signal quality across development stages. The system scores signals 0–10 and is available in two variants: ETS Electrode for material screening and ETS Device for full device comparison. It is built on a decade of B-Secur laboratory data.Business Wire BlogB-Secur and CSEM Partner to Bring Clinically-Validated Heart Monitoring to Health WearablesCSEM, a Swiss technology innovation center, and B-Secur, a Belfast-based biosensing technology company, have announced a partnership to integrate clinically-validated heart monitoring into health wearables by combining CSEM's PPG vital signs monitoring expertise with B-Secur's FDA 510(k)-cleared ECG algorithms. The collaboration offers device manufacturers an integrated solution for arrhythmia detection and cardiovascular health monitoring, with a route to regulatory clearance for clinical-grade applications. The global wearable healthcare devices market is projected to grow from $45 billion in 2025 to nearly $76 billion by 2030, according to MarketsandMarkets.Towards HealthcareBlood Pressure Measuring Devices Market to Grow at 9.1% CAGR till 2035The global blood pressure measuring devices market is projected to grow from USD 1.91 billion in 2025 to USD 4.56 billion by 2035, expanding at a compound annual growth rate of 9.1%, driven by rising hypertension prevalence, remote patient monitoring adoption, and technological advancements including AI-powered devices. Key market dynamics include North America holding the largest share in 2025 while Asia-Pacific is expected to register the fastest growth, supported by favorable government policies and aging populations worldwide. Industry developments include OMRON Healthcare's FDA De Novo application for AI-powered atrial fibrillation detection, Wellvii's partnership with B-Secur for ECG-enabled BP monitoring, and Sky Labs securing $15.3 million Series C funding for its AI-powered ring-type blood pressure monitor.YahooBiotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring PlatformBiotricity and B-Secur partnered to launch a device-neutral ambulatory cardiac monitoring platform combining B-Secur's FDA-cleared HeartKey technology with Biotricity's diagnostic solutions. The partnership targets healthcare providers and diagnostic facilities, citing a projected physician shortage of 124,000 by 2034 and CVD costs tripling to $1.8 trillion by 2050.PR NewswireBiotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring PlatformBiotricity and B-Secur partnered to launch a device-neutral ambulatory cardiac monitoring platform combining B-Secur's FDA-cleared HeartKey technology with Biotricity's diagnostic solutions. The partnership aims to address gaps in cardiac care, citing 90% of U.S. adults at CVD risk and a projected 124,000 physician shortage by 2034.Insider IntelligenceConsumers and physicians are at odds on the value of health wearablesA survey commissioned by B-Secur and conducted by Sage Growth Partners of 500 US adults and 85 healthcare providers found a significant perception gap: while 95% of wearable owners would share their health data with physicians and 61% trust device-generated heart health data, only 9% of providers find over 75% of consumer wearable data useful. The article notes that wearable manufacturers including Oura and Apple are taking steps to address physician accuracy concerns, with Oura releasing an improved ring and Apple gaining FDA qualification for its atrial fibrillation feature. An estimated 80 million Americans currently use health wearables, projected to rise to 90 million by 2028.Business Wire BlogMarket Report Highlights Opportunity for Consumer Wearables to Enhance Accuracy and Build Trust with ProvidersB-Secur released research showing a gap between consumer adoption and provider trust in wearable health devices. 95% of consumers would share device data with a medical professional, but only 9% of providers are very satisfied with consumer wearables for cardiac monitoring.YahooB-Secur Elevates Proactive, Efficient Cardiac Care with FDA-Cleared HeartKey® Rhythm SolutionB-Secur announced FDA clearance and launch of HeartKey Rhythm, a suite of ECG algorithms and analytics for ambulatory devices. The product reduces noise and improves signal clarity, with CEO Alan Foreman noting it is the company's second FDA clearance in four years.